Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy

I. Gataa, L. Mezquita, C. Rossoni, E. Auclin, M. Kossai, F. Aboubakar, S. Le Moulec, J. Masse, M. Masson, N. Radosevic-Robin, P. Alemany, M. Rouanne, V. Bluthgen, L. Hendriks, C. Caramella, A. Gazzah, D. Planchard, J.P. Pignon, B. Besse, J. Adam*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Web of Science)
Original languageEnglish
Pages (from-to)221-229
Number of pages9
JournalEuropean Journal of Cancer
Volume145
DOIs
Publication statusPublished - 1 Mar 2021

Keywords

  • Immunotherapy
  • Immune checkpoint inhibitor
  • Nivolumab
  • Tumor-infiltrating lymphocytes
  • TIL
  • Lung cancer
  • Nonesmall cell lung cancer
  • NSCLC
  • Prognostic
  • Biomarkers

Cite this